Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Leukemia & Lymphoma Society
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 12, 2023
Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Leukemia & Lymphoma Society
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Idarubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2018
Lead Product(s) : Idarubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idarubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : UMR1098, EFS BFC, Besançon | Centre Henri Becquerel | Maisonneuve-Rosemont Hospital | Centre Hospitalier Universitaire Dijon | INSERM CIC1431
Deal Size : Inapplicable
Deal Type : Inapplicable
Combination Chemotherapy in Patients With Newly Diagnosed BPDCN
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Idarubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : UMR1098, EFS BFC, Besançon | Centre Henri Becquerel | Maisonneuve-Rosemont Hospital | Centre Hospitalier Universitaire Dijon | INSERM CIC1431
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idarubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2016
Lead Product(s) : Idarubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable